NCT00067743View on ClinicalTrials.gov

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 31, 2003

Primary Completion Date

October 31, 2004

Study Completion Date

August 31, 2007

Conditions
Complex Regional Pain Syndrome (RSD)
Interventions
DRUG

Lenalidomide

supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day

Trial Locations (6)

19102

Drexel University College of Medicine, Philadelphia

21287

Johns Hopkins Hospital, Baltimore

27103

The Center for Clinical Research, Winston-Salem

92093

UCSD Center for Pain and Palliative Medicine, La Jolla

27599-7010

UNC Hospitals University of North Carolina, Chapel Hill

98122-4379

Swedish Pain Management, Seattle

Sponsors
All Listed Sponsors
lead

Celgene Corporation

INDUSTRY